Elevated RIPK1 protein levels correlate with IDH1 wild-type status and increased Ki67 expression, aligning with its association with glioma aggressiveness and correspondingly demonstrating the highest HR for reduced OS (Figs. 1D, G and 2A). Here, RIPK1 is linked to central nervous system cancer.